Novo Nordisk (NYSE:NVO) has seen a bullish sentiment from options traders, with 76% of detected trades being bullish. The options activity suggests an expected price window of $100.0 to $185.0. The company, a leader in diabetes-care products, has its stock price slightly down at $132.02, with analysts setting an average target price of $150.0. Cantor Fitzgerald analysts have given ratings with targets of $160 and $140.